IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

OBJECTIVES: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy. METHODS: 499 patients with inadequate response to one or more T...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, P, Keystone, E, Tony, H P, Cantagrel, A, van Vollenhoven, R, Sanchez, A, Alecock, E, Lee, J, Kremer, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811149/
https://www.ncbi.nlm.nih.gov/pubmed/18625622
http://dx.doi.org/10.1136/ard.2008.092932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811149/
https://www.ncbi.nlm.nih.gov/pubmed/18625622
http://dx.doi.org/10.1136/ard.2008.092932

Ejemplares similares